Brazil’s National Health Surveillance Agency (Anvisa) has authorized the first Phase 1 clinical trial evaluating the safety of polylaminin, an experimental laminin-derived biomolecule designed for acute spinal cord injury. The study, approved in January 2026, will enroll five adult patients with complete thoracic spinal cord injuries — a condition that typically results in paraplegia. The research is linked to work led by Brazilian neuroscientist Dr. Tatiana Sampaio at the Federal University of Rio de Janeiro (UFRJ).
Who Is Behind the Research?
Dr. Tatiana Sampaio, a Brazilian neuroscientist affiliated with UFRJ, has been publicly associated with the development and investigation of polylaminin over the past decade.
Earlier laboratory research on polylaminin — including studies published in peer-reviewed journals — demonstrated that the polymerized form of laminin could stimulate axonal growth and improve locomotor recovery in animal models of spinal cord injury.
Scientific publication reference:
https://pubmed.ncbi.nlm.nih.gov/20643907/
In media interviews, Sampaio has reported motor improvement in a limited number of paraplegic patients treated under experimental or compassionate-use contexts. However, these cases have not yet been validated through large-scale randomized controlled trials published in high-impact international medical journals.
What Is Polylaminin?
Polylaminin is a polymeric assembly of laminin, a structural protein found in the extracellular matrix that plays a critical role in neural development and axonal guidance.
Researchers hypothesize that polylaminin may function as:
-
A structural scaffold for axonal regrowth
-
A modulator of inflammatory response
-
A promoter of neural pathway stabilization
Unlike supportive care currently available for spinal cord injury, polylaminin is being investigated as a regenerative strategy.
The Clinical Trial: What Is Being Tested?
On January 5, 2026, Anvisa formally approved a Phase 1 clinical trial to evaluate safety and tolerability in humans.
Official regulatory source:
https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2026/anvisa-autoriza-pesquisa-clinica-para-avaliar-a-seguranca-do-uso-de-polilaminina-em-humanos
Ministry of Health announcement:
https://www.gov.br/saude/pt-br/assuntos/noticias/2026/janeiro/ministerio-da-saude-e-anvisa-anunciam-aprovacao-de-estudo-clinico-para-tratamento-inovador-de-lesoes-na-medula-espinhal
Study Design
-
Phase: Phase 1 (safety evaluation)
-
Participants: 5 adults
-
Condition: Complete thoracic spinal cord injury (T2–T10)
-
Clinical consequence: Typically results in paraplegia (paralysis of lower limbs)
-
Intervention: Single intramedullary injection of polylaminin
-
Objective: Assess safety, not efficacy
Phase 1 trials do not determine whether a treatment restores movement. They assess adverse effects and biological tolerability.
The Claim of Motor Recovery: What Is Known?
Reports circulating in Brazilian media indicate that six paraplegic patients treated experimentally with polylaminin experienced varying degrees of motor recovery.
At present:
-
These outcomes have not been confirmed through peer-reviewed randomized clinical trials.
-
No published Phase 2 or Phase 3 data are available.
-
The newly approved study remains focused exclusively on safety.
Medical experts emphasize that spinal cord regeneration research has historically faced significant translational challenges from animal models to human outcomes.
Why Spinal Cord Injury Research Matters
Spinal cord injury (SCI) is one of the most severe neurological conditions worldwide.
Global estimates indicate:
-
Hundreds of thousands of new cases annually
-
High rates of permanent disability
-
Limited regenerative treatment options
Complete thoracic injury often results in permanent paraplegia. Current standards of care focus primarily on stabilization and rehabilitation rather than neural regeneration.
Any therapy capable of restoring motor function would represent a major shift in neurological medicine. However, regulatory approval requires rigorous multi-phase clinical validation.
Scientific Caution and Next Steps
Anvisa’s approval marks a regulatory milestone, but not therapeutic confirmation.
Before any treatment can be approved for widespread medical use, it must demonstrate:
-
Safety (Phase 1)
-
Preliminary efficacy (Phase 2)
-
Large-scale efficacy and risk assessment (Phase 3)
Polylaminin remains an investigational therapy.
The scientific community will closely monitor data emerging from this trial to determine whether earlier experimental reports translate into measurable clinical benefit.
Key Takeaways
-
Polylaminin is an experimental laminin-based biomolecule under investigation for spinal cord injury.
-
Brazilian neuroscientist Dr. Tatiana Sampaio has been publicly associated with its development.
-
Anvisa approved the first Phase 1 human safety trial in January 2026.
-
The condition being studied typically results in paraplegia.
-
Claims of motor recovery in six patients have not yet been validated through large-scale peer-reviewed trials.
-
Clinical efficacy remains unproven.
Sources
Anvisa – Clinical Trial Authorization
https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2026/anvisa-autoriza-pesquisa-clinica-para-avaliar-a-seguranca-do-uso-de-polilaminina-em-humanos
Brazil Ministry of Health
https://www.gov.br/saude/pt-br/assuntos/noticias/2026/janeiro/ministerio-da-saude-e-anvisa-anunciam-aprovacao-de-estudo-clinico-para-tratamento-inovador-de-lesoes-na-medula-espinhal
FASEB Journal Study
https://pubmed.ncbi.nlm.nih.gov/20643907/
https://blog.dmixbrazil.com/brazilian-breakthrough-revolutionizing-tumor-treatment/
